NGNE — Neurogene Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1404644 ·
Last close
$23.10
Market Cap
$478.19M
52W High
$43.66
52W Low
$15.93
ADV30
333,315
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -32,376,000 | -29,023,000 | 377,901,000 | 78,942,000 | 23,107,000 |
| Jun 2026 | 0 | — | -36,670,000 | -34,488,000 | 244,364,000 | 112,485,000 | 27,231,000 |
| Mar 2026 | 0 | — | -33,349,000 | -30,934,000 | 263,141,000 | 124,161,000 | 25,358,000 |
| Dec 2025 | 0 | — | -27,529,000 | -24,735,000 | 288,604,000 | 103,845,000 | 23,717,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-96,454,000
Investing CF
$-84,041,000
Financing CF
$188,432,000
CapEx
$-1,078,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.96
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-447,094,000
Inventory
—
Receivables
$242,000
ST Investments
$280,776,000
EBIT TTM
$-119,179,000
Pretax Income TTM
$-119,180,000
Interest Exp TTM
$1,000
Analysts
8
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -103,328,000 | -90,351,000 | 288,604,000 | 23,717,000 | 264,887,000 | -77,173,000 |
| Dec 2024 | 925,000 | -82,605,000 | -75,144,000 | 335,730,000 | 25,355,000 | 310,375,000 | -70,603,000 |
| Dec 2023 | 0 | -55,583,000 | -36,317,000 | 222,573,000 | 36,549,000 | 186,024,000 | -51,422,000 |
| Dec 2022 | 0 | -56,517,000 | -55,189,000 | 109,265,000 | 255,004,000 | -145,739,000 | -52,824,000 |
TTM Snapshot
Revenues TTM
$1,101,000
NetIncome TTM
$-111,110,000
OpCashFlow TTM
—
Assets (Latest)
$244,364,000
Forward EPS
$-5.03
Max Pain — expiry 2027-12-17 (volume-derived — Yahoo OI feed degraded)
max pain strike: $35.00 · spot: $23.14 · call volume: 63 · put volume: 30
Expected Move to 2027-12-17:
±$17.00
(73.47%) —
implied range
$6.14 –
$40.14
· ATM straddle on $25.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IMMP | IMMUTEP Ltd | $480.43M | $3.26 | — |
| BLSM | BlossomHill Therapeutics, Inc. | $480.91M | $15.13 | — |
| MNPR | Monopar Therapeutics | $481.56M | $71.06 | — |
| AMRN | AMARIN CORP PLC\UK | $473.82M | $11.27 | — |
| KMDA | KAMADA LTD | $470.92M | $8.16 | — |
News headlines (Yahoo Finance, 1h cache)
Does Neurogene (NGNE) Have the Potential to Rally 203.28% as Wall Street Analysts Expect?
2026-11-11 20:19 · Yahoo
Neurogene: Q3 Earnings Snapshot
2026-11-09 12:35 · Yahoo
Neurogene Reports Third Quarter 2026 Financial Results and Highlights Recent Updates
2026-11-09 12:30 · Yahoo
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-11-05 21:01 · Yahoo
Neurogene to Participate in Upcoming Investor Conferences
2026-11-03 12:30 · Yahoo
Neurogene Presents New Data at ESGCT Congress that Reinforce Key Differentiators of NGN-401 Gene Therapy for Rett Syndrome
2026-10-27 11:30 · Yahoo
Neurogene Announces Upcoming Presentations Highlighting Key Differentiators of NGN-401 for Rett Syndrome at the ESGCT 33rd Annual Congress
2026-10-20 11:30 · Yahoo
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-10-05 20:01 · Yahoo
Neurogene to Participate in H.C. Wainwright 28th Annual Global Investment Conference
2026-09-08 11:30 · Yahoo
Neurogene Inc. Announces Pricing of $125 Million Public Offering
2026-07-01 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.